Skip to main navigation
Skip to search
Skip to main content
Johns Hopkins University Home
Home
Profiles
Research units
Research output
Search by expertise, name or affiliation
The Future of HCV Therapy: With or without Interferon and Ribavirin?
Mark Sulkowski
School of Medicine
Research output
:
Chapter in Book/Report/Conference proceeding
›
Chapter
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'The Future of HCV Therapy: With or without Interferon and Ribavirin?'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine & Life Sciences
Ribavirin
100%
Interferons
81%
Antiviral Agents
32%
Protease Inhibitors
26%
peginterferon alfa-2b
20%
N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide
19%
peginterferon alfa-2a
19%
telaprevir
19%
Phase II Clinical Trials
15%
Therapeutics
14%
Chronic Hepatitis
13%
Hepatitis C
12%
Peptide Hydrolases
10%
Genotype
9%
Viruses
8%
In Vitro Techniques
5%
Pharmaceutical Preparations
5%